Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

Erythroid Specificity and Safety of Globin-Encoding Lentiviral Vectors

Annalisa Cabriolu, PhD, Ashlesha Odak, MS, Friederike Kogel, MD, Michel Sadelain, MD PhD

Blood (2020) 136 (Supplement 1): 29.

https://doi.org/10.1182/blood-2020-142989

Published: 2020

Journal Articles

A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory B-Cell Malignancies

Jae H. Park, MD, Isabelle Riviere, PhD, Devanjan S. Sikder, Vladimir P. Bermudez, Brigitte Senechal, Xiuyan Wang, PhD, Thomas H. Auchincloss, Claudia Diamonte, RN, Elizabeth Halton, NP-BC AOCNP, M. Lia Palomba, MD, Renier J. Brentjens, MD PhD, Michel Sadelain, MD PhD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-143088

Published: 2020

Journal Articles

NOTCH and CAR Signaling Control T Cell Lineage Commitment from Pluripotent Stem Cells

Sjoukje van der Stegen, PhD, Pieter Lindenbergh, Roseanna Petrovic, PhD, Benjamin Whitlock, PhD, Raedun Clarke, PhD, Bahram Valamehr, PhD, Isabelle Riviere, PhD, Michel Sadelain, MD PhD

Blood (2020) 136 (Supplement 1): 30.

https://doi.org/10.1182/blood-2020-142894

Published: 2020

Journal Articles

Loss of TET2 Uncouples Proliferative and Effector Functions in CAR T Cells

Nayan Jain, Zeguo Zhao, PhD, Archana S. Iyer, PhD, Michael Lopez, Judith Feucht, MD, Richard P. Koche, PhD, Yingqian Zhan, Michel Sadelain, MD PhD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-142957

Published: 2020

Journal Articles

Targeted Integration of a CAR at a Novel Genomic Safe Harbor Directs Potent Therapeutic Outcomes

Ashlesha Odak, MS, Han Yuan, PhD, Judith Feucht, MD, Jorge Mansilla - Soto, PhD, Justin Eyquem, PhD, Christina Leslie, PhD, Michel Sadelain, MD PhD

Blood (2020) 136 (Supplement 1): 28.

https://doi.org/10.1182/blood-2020-141967

Published: 2020

Journal Articles

MSKCC Early Experience Using Radiotherapy As a Bridging Strategy for Relapsed Diffuse Large B Cell Lymphoma before CD19 CAR T Therapy

Brandon Imber, MD MA, M. Lia Palomba, MD, Carl DeSelm, MD PhD, Connie Lee Batlevi, MD PhD, Parastoo B. Dahi, MD, Sergio A. Giralt, MD, Ariela Noy, MD, Jae H. Park, MD, Craig S. Sauter, MD, Michael Scordo, MD, Gunjan L. Shah, MDMS, Michel Sadelain, MD PhD, Miguel-Angel Perales, MD, Joachim Yahalom, MD

Blood (2019) 134 (Supplement_1): 3238.

https://doi.org/10.1182/blood-2019-131449

Published: 2019

Journal Articles

Early Experience Using Radiotherapy As a Salvage Treatment for Relapsed or Refractory Non-Hodgkin Lymphomas Following CD19 Chimeric Antigen Receptor Modified T-Cell Therapy

Brandon Imber, MD MA, M. Lia Palomba, MD, Carl DeSelm, MD PhD, Parastoo B. Dahi, MD, Craig S. Sauter, MD, Michael Scordo, MD, Connie Lee Batlevi, MD PhD, Jae H. Park, MD, Gunjan L. Shah, MDMS, Sergio A. Giralt, MD, Miguel-Angel Perales, MD, Michel Sadelain, MD PhD, Joachim Yahalom, MD

Blood (2019) 134 (Supplement_1): 3244.

https://doi.org/10.1182/blood-2019-129620

Published: 2019

Journal Articles

FT819: Translation of Off-the-Shelf TCR-Less Trac-1XX CAR-T Cells in Support of First-of-Kind Phase I Clinical Trial

Blood (2019) 134 (Supplement_1): 4434.

https://doi.org/10.1182/blood-2019-130584

Published: 2019

Journal Articles

Clinical Factors Associated with Improved Survival Following Allogeneic HSCT after CD19 CAR Therapy in Adult Patients with Relapsed B-ALL

Jae H. Park, MD, Jessica Flynn, BS, Mithat Gonen, Yvette Bernal, MS, Claudia Diamonte, RN, Elizabeth Halton, NP-BC AOCNP, Xiuyan Wang, PhD, Isabelle Riviere, PhD, Michel Sadelain, MD PhD, Renier J. Brentjens, MD PhD

Blood (2019) 134 (Supplement_1): 1348.

https://doi.org/10.1182/blood-2019-129343

Published: 2019

Journal Articles

Potent Synergy between Combination of Chimeric Antigen Receptor (CAR) Therapy Targeting CD19 in Conjunction with Dendritic Cell (DC)/Tumor Fusion Vaccine in Hematological Malignancies

Marzia Capelletti, PhD MMSc, Jessica Liegel, MD, Maria Themeli, MD PhD, Tuna Mutis, Dina Stroopinsky, PhD, Shira Orr, PhD, Daniela Torres, Adam Morin, Gertrude Gunset, BA, Haider Ghiasuddin, Maryam Rahimian, MD, Myrna Nahas, MD, Lina Bisharat, Shufen Meng, MD, Nikhil C. Munshi, MD, Donald Kufe, MD, Jacalyn Rosenblatt, MD, Michel Sadelain, MD PhD, David E. Avigan, MD

Blood (2019) 134 (Supplement_1): 3227.

https://doi.org/10.1182/blood-2019-124944

Published: 2019

Journal Articles

Pluripotent Cell-Derived Off-the-Shelf TCR-Less CAR-Targeted Cytotoxic T Cell Therapeutic for the Allogeneic Treatment of B Cell Malignancies

Blood (2018) 132 (Supplement 1): 4546.

https://doi.org/10.1182/blood-2018-99-116843

Published: 2018

Journal Articles

Calibrated CAR Activation Potential Directs Alternative T Cell Fates and Therapeutic Potency

Judith Feucht, MD, Jie Sun, PhD, Justin Eyquem, PhD, Yu-Jui Ho, PhD, Zeguo Zhao, PhD, Josef Leibold, MD, Anton Dobrin, Annalisa Cabriolu, PhD, Mohamad Hamieh, PhD, Michel Sadelain, MD PhD

Blood (2018) 132 (Supplement 1): 1412.

https://doi.org/10.1182/blood-2018-99-117698

Published: 2018

Journal Articles

A Phase I First-in-Human Clinical Trial of CD19-Targeted 19-28z/4-1BBL "Armored" CAR T Cells in Patients with Relapsed or Refractory NHL and CLL Including Richter's Transformation

Jae H. Park, MD, Maria Lia Palomba, MD, Connie Lee Batlevi, MD, Isabelle Riviere, PhD, Xiuyan Wang, PhD, Brigitte Senechal, PhD, Richard R. Furman, MD, Yvette Bernal, MS, Malloury Hall, BA, John Pineda, RN, Claudia Diamonte, RN, Elizabeth Halton, NP-BC AOCNP, Renier J. Brentjens, MD PhD, Michel Sadelain, MD PhD

Blood (2018) 132 (Supplement 1): 224.

https://doi.org/10.1182/blood-2018-99-117737

Published: 2018

Journal Articles

Safety and Efficacy Trial of Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells (HPCs) for Globin Gene Transfer in Patients with Sickle Cell Disease

Farid Boulad, MD, Tsiporah B. Shore, MD, Koen Van Besien, MD PhD, Danielle Guarneri, June Greenberg, RN, Caterina Minniti, MD, Sylvie wiener Fedus, Fabiana Perna, MD, Xiuyan Wang, PhD, Isabelle Riviere, PhD, Michel Sadelain, MD PhD, Patricia Shi, MD

Blood (2017) 130 (Supplement 1): 3531.

https://doi.org/10.1182/blood.V130.Suppl_1.3531.3531

Published: 2017

Journal Articles

Systematic Combinatorial Chimeric Antigen Receptor Therapies to AML

Fabiana Perna, MD, Samuel Berman, Rajesh K Soni, PhD, Jorge Mansilla-Soto, PhD, Justin Eyquem, PhD, Mohamad Hamieh, PhD, Ronald C Hendrickson, PhD, Cameron Brennan, MD, Michel Sadelain, MD PhD

Blood (2017) 130 (Supplement 1): 856.

https://doi.org/10.1182/blood.V130.Suppl_1.856.856

Published: 2017

Journal Articles

Studies of White Cell, Platelet, and Coagulation Activation with Plerixafor Administration in Patients with Sickle Cell Disease

Petra Pham, Mihaela Barbu-Stevanovic, June Greenberg, RN, Danielle Guarneri, Beau Mitchell, MD, Caterina Minniti, MD, Mohandas Narla, DSc, Karina Yazdanbakhsh, PhD, Tsiporah B. Shore, MD, Farid Boulad, MD, Michel Sadelain, MD PhD, Patricia Shi, MD

Blood (2017) 130 (Supplement 1): 963.

https://doi.org/10.1182/blood.V130.Suppl_1.963.963

Published: 2017

Journal Articles

Generation of Clonal Antigen Specific CD8αβ + Cytotoxic T Lymphocytes from Renewable Pluripotent Stem Cells for Off-the-Shelf T Cell Therapeutics

Sjoukje Van Der Stegen, PhD, Raedun Clarke, PhD, Jorge Mansilla - Soto, PhD, Edwin Ortiz, Chia-Wei Chang, Jeff Sasaki, Tom Lee, PhD, Weijie Lan, PhD, Daniel Shoemaker, PhD, Isabelle Riviere, PhD, Bahram Valamehr, PhD, Michel Sadelain, MD PhD

Blood (2017) 130 (Supplement 1): 163.

https://doi.org/10.1182/blood.V130.Suppl_1.163.163

Published: 2017

Journal Articles

High Dose Cyclophosphamide and Pre-Treatment Disease Burden Dictate Response and Survival in a Multicenter Clinical Trial Using CD19-Specific CAR T Cells for Relapsed/Refractory B-ALL

Blood (2017) 130 (Supplement 1): 1326.

https://doi.org/10.1182/blood.V130.Suppl_1.1326.1326

Published: 2017

Journal Articles

Probing the AML Surfaceome for Chimeric Antigen Receptor (CAR) Targets

Fabiana Perna, MDPhD, Samuel Berman, Jorge Mansilla-Soto, PhD, Mohamad Hamieh, PhD, Rupa Juthani, MD, Rajesh Soni, PhD, Justin Eyquem, PhD, Ronald Hendrickson, PhD, Cameron Brennan, MD, Michel Sadelain, MD PhD

Blood (2016) 128 (22): 526.

https://doi.org/10.1182/blood.V128.22.526.526

Published: 2016

Journal Articles

Implications of Minimal Residual Disease Negative Complete Remission (MRD-CR) and Allogeneic Stem Cell Transplant on Safety and Clinical Outcome of CD19-Targeted 19-28z CAR Modified T Cells in Adult Patients with Relapsed, Refractory B-Cell ALL

Jae H Park, MD, Isabelle Riviere, PhD, Xiuyan Wang, PhD, Yvette Bernal, MS, Terence Purdon, Elizabeth Halton, RN, MS, ANP, Yongzeng Wang, PhD, Kevin J. Curran, MD, Craig S. Sauter, MD, Michel Sadelain, MD PhD, Renier J. Brentjens, MD PhD

Blood (2015) 126 (23): 682.

https://doi.org/10.1182/blood.V126.23.682.682

Published: 2015

NARROW

Erythroid Specificity and Safety of Globin-Encoding Lentiviral Vectors

A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory B-Cell Malignancies

NOTCH and CAR Signaling Control T Cell Lineage Commitment from Pluripotent Stem Cells

Loss of TET2 Uncouples Proliferative and Effector Functions in CAR T Cells

Targeted Integration of a CAR at a Novel Genomic Safe Harbor Directs Potent Therapeutic Outcomes

MSKCC Early Experience Using Radiotherapy As a Bridging Strategy for Relapsed Diffuse Large B Cell Lymphoma before CD19 CAR T Therapy

Early Experience Using Radiotherapy As a Salvage Treatment for Relapsed or Refractory Non-Hodgkin Lymphomas Following CD19 Chimeric Antigen Receptor Modified T-Cell Therapy

FT819: Translation of Off-the-Shelf TCR-Less Trac-1XX CAR-T Cells in Support of First-of-Kind Phase I Clinical Trial

Clinical Factors Associated with Improved Survival Following Allogeneic HSCT after CD19 CAR Therapy in Adult Patients with Relapsed B-ALL

Potent Synergy between Combination of Chimeric Antigen Receptor (CAR) Therapy Targeting CD19 in Conjunction with Dendritic Cell (DC)/Tumor Fusion Vaccine in Hematological Malignancies

Pluripotent Cell-Derived Off-the-Shelf TCR-Less CAR-Targeted Cytotoxic T Cell Therapeutic for the Allogeneic Treatment of B Cell Malignancies

Calibrated CAR Activation Potential Directs Alternative T Cell Fates and Therapeutic Potency

A Phase I First-in-Human Clinical Trial of CD19-Targeted 19-28z/4-1BBL "Armored" CAR T Cells in Patients with Relapsed or Refractory NHL and CLL Including Richter's Transformation

Safety and Efficacy Trial of Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells (HPCs) for Globin Gene Transfer in Patients with Sickle Cell Disease

Systematic Combinatorial Chimeric Antigen Receptor Therapies to AML

Studies of White Cell, Platelet, and Coagulation Activation with Plerixafor Administration in Patients with Sickle Cell Disease

Generation of Clonal Antigen Specific CD8αβ + Cytotoxic T Lymphocytes from Renewable Pluripotent Stem Cells for Off-the-Shelf T Cell Therapeutics

High Dose Cyclophosphamide and Pre-Treatment Disease Burden Dictate Response and Survival in a Multicenter Clinical Trial Using CD19-Specific CAR T Cells for Relapsed/Refractory B-ALL

Probing the AML Surfaceome for Chimeric Antigen Receptor (CAR) Targets

Implications of Minimal Residual Disease Negative Complete Remission (MRD-CR) and Allogeneic Stem Cell Transplant on Safety and Clinical Outcome of CD19-Targeted 19-28z CAR Modified T Cells in Adult Patients with Relapsed, Refractory B-Cell ALL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only